---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021833"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:49:16.238152+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioAtla reports Q3 net loss $25.8M; cash $178.1M; BA3011 NSCLC shows 50% ORR in monotherapy

## Summary
- Cash and cash equivalents $178.1M as of Sep 30, 2022, expected to fund operations into 2H24.
- Net loss $25.8M for Q3 2022 vs $22.9M in Q3 2021; R&D expense increased to $19.8M.
- BA3011 Phase 2 NSCLC: 4 PRs in monotherapy (ORR 50%) in non-squamous group; 1 CR in combination.
- BA3011 UPS part 2 enrollment anticipated to start by year-end after FDA feedback; potential registrational path.
- BA3071 Phase 1: first two cohorts completed without DLTs or SAEs; BA3182 IND on track by year-end.

## SEC filing metadata
- accession: 0000950170-22-021833
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000095017022021833/0000950170-22-021833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000095017022021833/bcab-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021833
- JSON: https://secwatch.observer/filing/0000950170-22-021833.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021833.txt

## Key facts
- Earnings Releases
  BioAtla, Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: BioAtla, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826892/000095017022021833/0000950170-22-021833-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.